Aligos Therapeutics, Inc. (NASDAQ:ALGS) Given Average Rating of “Hold” by Brokerages

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGSGet Rating) have received a consensus rating of “Hold” from the six ratings firms that are presently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $7.00.

ALGS has been the subject of several analyst reports. Zacks Investment Research lowered shares of Aligos Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, May 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aligos Therapeutics in a research report on Friday, April 1st. SVB Leerink downgraded shares of Aligos Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 5th. Finally, Piper Sandler downgraded shares of Aligos Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $15.00 to $4.00 in a research report on Wednesday, March 23rd.

Aligos Therapeutics stock opened at $1.15 on Wednesday. Aligos Therapeutics has a 52-week low of $1.03 and a 52-week high of $34.31. The firm has a 50 day moving average price of $1.67 and a two-hundred day moving average price of $5.74. The firm has a market cap of $49.10 million, a price-to-earnings ratio of -0.35 and a beta of 3.52.

Aligos Therapeutics (NASDAQ:ALGSGet Rating) last released its quarterly earnings results on Wednesday, May 4th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.11). Aligos Therapeutics had a negative return on equity of 75.34% and a negative net margin of 2,263.64%. During the same quarter in the prior year, the business posted ($0.74) EPS. Equities research analysts expect that Aligos Therapeutics will post -2.95 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada grew its position in Aligos Therapeutics by 103.8% in the 2nd quarter. Royal Bank of Canada now owns 1,284 shares of the company’s stock valued at $26,000 after purchasing an additional 654 shares during the period. Citigroup Inc. boosted its holdings in Aligos Therapeutics by 49.7% during the 3rd quarter. Citigroup Inc. now owns 3,122 shares of the company’s stock worth $48,000 after acquiring an additional 1,037 shares during the last quarter. O Shaughnessy Asset Management LLC purchased a new position in Aligos Therapeutics during the 3rd quarter worth $51,000. Advisor Group Holdings Inc. purchased a new position in Aligos Therapeutics during the 3rd quarter worth $70,000. Finally, Cubist Systematic Strategies LLC purchased a new position in Aligos Therapeutics during the 4th quarter worth $60,000. 70.21% of the stock is owned by institutional investors and hedge funds.

Aligos Therapeutics Company Profile (Get Rating)

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB.

Further Reading

Analyst Recommendations for Aligos Therapeutics (NASDAQ:ALGS)

Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.